In cohort 1 of the ATLANTIC (advanced non-small-cell lung cancer) study, a single arm phase II trial—111 EGFR+/ALK+ NSCLC-affected patients with ≥25% (74 patients) or <25% (37 patients) PD-L1 expression progressing after at least two previous lines of treatment (but ICIS-treatment naive) received durvalumab, an anti-PD-L1 antibody, for up to one year; as a result, in 12.2% of patients with ≥25% PD-L1 expression, an objective response was noted, as were favorable safety and tolerability profiles [33]. This evidence concerns the gene ALK and non-small cell lung carcinoma.